Helicobacter pylori infection Helicobacter pylori
Conditions
Interventions
(1)Dual therapy
Vonoprazan (20mg) given on twice daily and
Amoxicillin (500mg) given on hour times daily
For 7 days
(2)Triple therapy
Vonoprazan (20mg), amoxicillin (500mg), and clarithromycin (400mg)
Sponsors
Sue Soichiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients infected with Helicobacter pylori. Positive patients by Urea breath test, stool Helicobacter pylori antigen test, Helicobacter pylori culture, anti-Helicobacter pylori antibody test (blood), rapid urease test (biopsy sample), or histological diagnosis (biopsy sample) are treat with infected. Patients who give a written informed consent.
Exclusion criteria
Exclusion criteria: Patients who have Helicobacter pylori eradication history. Pregnancy or lactation. Past history of allergy for the drugs used in this therapy. Patients with infectious mononucleosis. Patients using atazanavir, rilpivirine, pimozide, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, dihydroergotamine mesylate, suvorexant, daridorexant hydrochloride, vornorexant hydrate, lomitapide mesylate, tadalafil (Adcirca), ticagrelor, ibrutinib, ivabradine hydrochloride, venetoclax (during the dose titration phase), lurasidone hydrochloride, anamorelin hydrochloride, finerenone, isavuconazonium sulfate, voclosporin, or mavacamten. Patients using colchicine with liver dysfunction or renal dysfunction. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patients who are disqualified for the study by phyusicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Eradication rate (PPS) | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Eradication rate (PPS) (2) Safety | — |
Contacts
Public ContactSoichiro Sue
Yokohama City University Hospital
Outcome results
None listed